ORPHA:217067
Pouchitis
Publications
4,788
91th percentile
Trials
41
Interventional, condition-specific
Researchers
1,152
Distinct authors in sample
Gene link
—
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare intestinal disease characterized by non-specific inflammation of the ileal reservoir following ileal pouch anal anastomosis surgery. It generally occurs after the restoration of the fecal stream through the pouch and may be classified as acute or chronic, depending on the symptom duration (less or more than 4 weeks). Clinical presentation is variable and unspecific and commonly includes increased stool frequency and fluidity, rectal bleeding, abdominal cramps, bowel urgency, tenesmus, and nocturnal bowel incontinence.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005312
- MeSH:D019449
- UMLS:C0376620
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
4,788 matched papers (2,330 in last 10 years) Source
- Phenotype characterisedPresent
10 HPO annotations (e.g. Diarrhea; Abdominal pain; Abdominal cramps) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
5 FDA · 2 EMA designations (5 FDA orphan-indication approvals) — e.g. vedolizumab Source
- Interventional trialPresent
41 matched on ClinicalTrials.gov (9 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
10
Associated phenotypes · MONDO:0005312
- Diarrhea
- Abdominal pain
- Abdominal cramps
- Clostridium difficile colitis
- Anal pain
Showing 5 of 10 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
7
Designations · 5 with FDA orphan-indication approval
- FDA vedolizumabPouchitis · 2021-03-15 · Not FDA Approved for Orphan Indication
- FDA metronidazolePouchitis · 2011-04-26 · Not FDA Approved for Orphan Indication
- FDA metronidazolePouchitis · 2008-09-17 · Not FDA Approved for Orphan Indication
- FDA alicaforsenPouchitis · 2008-06-24 · Not FDA Approved for Orphan Indication
- FDA ClotrimazolePouchitis · 2005-06-14 · Not FDA Approved for Orphan Indication
- EMA MetronidazoleTreatment of pouchitis · 21/06/2011 · PositiveEMA designation
- EMA alicaforsenTreatment of pouchitis · 15/05/2009 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
15
Drugs / clinical candidates · MONDO_0005312
- ALICAFORSEN·phase 3
- USTEKINUMAB·phase 3
- VEDOLIZUMAB·phase 3
- CHARCOAL, ACTIVATED·phase 2
- TOFACITINIB·phase 2
- VIMEKOFUSP·phase 2
- HYDROXOCOBALAMIN·phase 1
- CLOTRIMAZOLE·phase 1 2
- FOSFOMYCIN·phase 1 2
- METRONIDAZOLE·phase 1 2
- MOLGRAMOSTIM·phase 1 2
- REGRAMOSTIM·phase 1 2
- SARGRAMOSTIM·phase 1 2
- TAURURSODIOL·phase 2 3
- URSODIOL·phase 2 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
4,788
4,788 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,788 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
2,330 in the last 10 years · medium confidence · 91th percentile (publications denominator)
Phrase hits: 4,788 · MeSH hits: 187
Who's working on it?
1,152
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Barnes EL14 papers · 2026
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Papers in Europe PMC - 02Kayal M8 papers · 2026
Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA .
Papers in Europe PMC - 03Farraye FA7 papers · 2026
Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Papers in Europe PMC - 04Segal JP7 papers · 2026
Department of Gastroenterology, Royal Melbourne Hospital, Parkville, VIC, Australia.
Papers in Europe PMC - 05Shen B7 papers · 2026
Columbia University Irving Medical Center/Herbert Irving Pavilion, New York, New York.
Papers in Europe PMC - 06Fischman M6 papers · 2026
Department of Military Medicine, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Papers in Europe PMC - 07Hashash JG6 papers · 2026
Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
Papers in Europe PMC - 08Herfarth HH6 papers · 2026
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Papers in Europe PMC - 09Jairath V6 papers · 2026
Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Alimentiv, London, Ontario, Canada. Electronic address: vjairath@uwo.ca.
Papers in Europe PMC - 10Alsakarneh S5 papers · 2026
Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
41
interventional trials for this specific condition
41 interventional trials matched this specific condition name; 9 currently recruiting in our sample.
Data as of 11 September 2026
41 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.8th percentile).
medium confidence · 96.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
41 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06443502·RECRUITING·A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
Not reviewed·Conditions: Pouchitis·Matched via name + MeSH
- NCT06864403·RECRUITING·Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Not reviewed·Conditions: Pouchitis · Pouches, Ileoanal · Pouch, Ileal·Matched via name + MeSH
- NCT06312683·RECRUITING·Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Not reviewed·Conditions: Pouchitis·Matched via name + MeSH
- NCT06861140·NOT YET RECRUITING·Exploring the Influence of Trptophan on the Treatment of Pouchitis
Not reviewed·Conditions: Pouchitis·Matched via name + MeSH
- NCT06916390·RECRUITING·GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis
Not reviewed·Conditions: Pouchitis·Matched via name + MeSH
- NCT07240649·NOT YET RECRUITING·Emerging Indications for Hyperbaric Oxygen Treatment
Not reviewed·Conditions: Post-COVID-19 Condition · Ulcerative Colitis · Crohn Disease · Calciphylaxis·Matched via name + MeSH
- NCT05829109·RECRUITING·Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Not reviewed·Conditions: Chronic Pouchitis · Pouchitis·Matched via name + MeSH
- NCT07486921·RECRUITING·Etrasimod as Prevention of Pouchitis
Not reviewed·Conditions: Pouchitis·Matched via name + MeSH
- NCT03545386·RECRUITING·Fecal Microbiota Transplantation for Pouchitis
Not reviewed·Conditions: Pouchitis·Matched via name + MeSH
Observational and natural-history studies
7 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- isrctn·ISRCTN83399182·No longer recruiting·A randomised controlled pilot study in the use of hyperbaric oxygen therapy versus metronidazole in chronic pouchitis
skipped — LLM skipped (--skip-llm)
- ctis·2025-521683-35-00·Authorised, ongoing·GUselkumAb inteRvention and DIet evaluAtioN for pouchitis
skipped — LLM skipped (--skip-llm)
- ctis·2024-517764-38-00·Authorised, ongoing·A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery. A clinical safety and proof-of-concept study
skipped — LLM skipped (--skip-llm)
- ctis·2024-517078-52-00·Expired·Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota transplant in UC with ileo-anal anastomosis.
skipped — LLM skipped (--skip-llm)
- ctis·2023-504773-20-00·Authorised, recruiting·An Open Label Single-Arm Phase 3 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Vedolizumab Intravenous in the Treatment of Pediatric Subjects with Active Chronic Pouchitis
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pouchitis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pouchitis"
MeSH descriptor terms unioned into the query: Pouchitis
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pouchitis"
Interventional trials matched via: both (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 41 interventional · 7 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:45:16.034Z
